It’s a bit cryptic …
From the quarterly on the 30th Jan it was said ….
“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”
From today’s Ann …
Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.
Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.
6 and 8 presumably that’s the 14 patients in question from 1b trail
No mention of any deaths …
These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.
And importantly, … Three (3) patients remain on trial from the Phase 1b cohort.
.
- Forums
- ASX - By Stock
- ATX
- Ann: Update on ACCENT Trial in Pancreatic Cancer
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-7
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.83M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 66032 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 4607 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 66032 | 0.061 |
1 | 18767 | 0.060 |
3 | 103326 | 0.059 |
1 | 85991 | 0.058 |
1 | 42105 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 4607 | 1 |
0.066 | 83586 | 1 |
0.070 | 6009 | 1 |
0.074 | 73026 | 1 |
0.075 | 335646 | 1 |
Last trade - 10.27am 01/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online